Role of age and comorbidities in mortality of patients with infective endocarditis

Carlos Armiñanzas1, Concepción Fariñas-Alvarez2, Jesús Zarauza3

  • 1Infectious Diseases Unit, Hospital Universitario Marqués de Valdecilla, University of Cantabria, IDIVAL, Santander, Spain.

Insights

Infective endocarditis (IE) patients aged 80 and older face higher mortality, alongside high comorbidity and non-performed surgery. The Charlson Comorbidity Index (CCI) aids in predicting mortality risk for IE patients, especially younger ones.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Geriatrics

Background:

  • Infective endocarditis (IE) is a serious infection affecting heart valves.
  • Patient characteristics and outcomes can vary significantly with age.
  • Predicting mortality risk in IE is crucial for clinical management.

Purpose of the Study:

  • To analyze IE patient characteristics across three age groups: <65, 65-80, and ≥80 years.
  • To assess the predictive ability of age and the Charlson Comorbidity Index (CCI) for mortality in IE patients.

Main Methods:

  • Prospective cohort study of 3120 IE patients from the GAMES Spanish database (2008-2015).
  • Patients stratified into age groups: <65, 65-80, and ≥80 years.
  • Area Under the Receiver-Operating Characteristic (AUROC) curve used to evaluate CCI's diagnostic accuracy for mortality risk.

Main Results:

  • No significant differences in IE clinical presentation (fever, heart failure) across age groups.
  • Lower surgical rates observed in patients ≥80 years (14.3%) compared to younger groups.
  • In-hospital mortality was 20.3% (<65), 30.1% (65-79), and 34.7% (≥80 years).
  • 1-year mortality was 3.2% (<65), 5.5% (65-80), and 7.6% (≥80 years).
  • Independent mortality predictors: age ≥80 (HR: 2.78), CCI ≥3 (HR: 1.62), and non-performed surgery (HR: 1.64).
  • CCI showed higher predictive accuracy for mortality in patients <65 years.

Conclusions:

  • Age ≥80 years, high comorbidity (CCI), and non-performed surgery are independent predictors of mortality in IE.
  • CCI can help identify IE patients, particularly those <65 years, with surgical indications who have a lower risk of mortality post-surgery.
Abstract

Related Concept Videos

Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
478
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
195
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
266
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
239
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
203
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
245